Review ArticlePotential Medication Treatment According to Pathological Mechanisms in Abdominal Aortic AneurysmZhang, Shi-lan MD, PhD*; Du, Xiao MD, PhD*; Chen, Yan-qiao MD*; Tan, Yuan-sheng MD, PhD†; Liu, Ling MD, PhD*Author Information *Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; and †Key laboratory for disease prevention and control of research by Traditional Chinese medicine and achievements transformation, Ministry of Education, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha, Hunan, China. Reprints: Ling Liu, PhD, Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, No.139 Renmin Rd, Changsha, Hunan 410011, China (e-mail addresses: [email protected]). Supported by the National Natural Science Foundation of China projects (No. 81470577 and 81473616). The authors report no conflicts of interest. Journal of Cardiovascular Pharmacology: January 2018 - Volume 71 - Issue 1 - p 46-57 doi: 10.1097/FJC.0000000000000540 Buy Metrics Abstract Abdominal aortic aneurysm (AAA) is a vascular disease with high mortality. Because of the lack of effective medications to stop or reverse the progression of AAA, surgical operation has become the most predominant recommendation of treatment for patients. There are many potential mechanisms, including inflammation, smooth muscle cell apoptosis, extracellular matrix degradation, oxidative stress, and so on, involving in AAA pathogenesis. According to those mechanisms, some potential therapeutic drugs have been proposed and tested in animal models and even in clinical trials. This review focuses on recent advances in both pathogenic mechanisms and potential pharmacologic therapies of AAA. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.